VASOPRESSIN | A211538 | EAGLE PHARMACEUTICALS INC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
PAR PHARMACEUTICAL, INC. et al v. EAGLE PHARMACEUTICALS, INC. 1 patentANDA 211538vasopressin | D.N.J. | 2020-12-07 | Terminated 2022-05-10 | — |
Par Pharmaceutical, Inc. et al v. Eagle Pharmaceuticals, Inc. 6 patentsANDA 211538Vasopressin | D. Del. | 2018-05-31 | Terminated 2021-09-16 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Axinn on behalf of Par Sterile Products LLC FDA-2021-P-1211 · 7 docket documents Attorney Chad Landmon of Axinn law firm filed this citizen petition on behalf of Par Sterile Products LLC pursuant to Section 505 of the Federal Food, Drug, and Cosmetic Act, requesting that the FDA refrain from approving Eagle Pharmaceuticals' ANDA No. 211538 for a generic vasopressin product (refe | 505(q) | 2021-11-09 | Denied | Par Sterile Products LLC |
Citizen Petition from Eagle Pharmaceuticals FDA-2021-P-0895 · 3 docket documents Eagle Pharmaceuticals filed a citizen petition under 21 C.F.R. § 10.30 and section 505(q) of the Federal Food, Drug, and Cosmetic Act requesting that the FDA neither approve nor maintain approval of any ANDA or 505(b)(2) NDA for vasopressin, 8-L-arginine that is not currently being marketed, unless | 505(q) | 2021-08-12 | Denied | Eagle Pharmaceuticals |
Source: Regulations.gov. FDA citizen petitions matched by application number.
No patent or exclusivity listings for this strength.